Brief: Cullinan Oncology Announces Clinical And Regulatory Update For CLN-081 In NSCLC EGFR Exon 20 Patients

Cullinan Therapeutics

28/03/2022 21:02

March 28 (Reuters) - Cullinan Oncology Inc  CGEM.O :
    * CULLINAN ONCOLOGY ANNOUNCES CLINICAL AND REGULATORY UPDATE
FOR
CLN-081 IN NSCLC EGFR EXON 20 PATIENTS
    * CULLINAN ONCOLOGY INC - CONTINUED FAVORABLE SAFETY AND
TOLERABILITY PROFILE OBSERVED IN HEAVILY PRE-TREATED PATIENTS
    * CULLINAN ONCOLOGY INC - PIVOTAL STUDY INITIATION EXPECTED
2H
2022 FOLLOWING FOOD EFFECT STUDY
    * CULLINAN ONCOLOGY INC - CONFIRMED OVERALL RESPONSE RATE
IMPROVES
TO 41% AT 100MG BID DOSE LEVEL

Source text for Eikon:  ID:nGNX2KMnwc 
Further company coverage:  CGEM.O 

 ((Reuters.Briefs@thomsonreuters.com;))